CytoDel Overview

  • Founded
  • 2012
Founded
  • Status
  • Private
  • Employees
  • 7
Employees
  • Latest Deal Type
  • Accelerator/​Inc
  • Investors
  • 3

CytoDel General Information

Description

Provider of a biotechnology platform intended to produce recombinant derivatives of botulinum neurotoxin. The company's platform manipulates the bont molecule into a drug delivery vehicle that can deliver therapeutic molecules to the inside of neurons with important implications, enabling medical researchers to develop drugs and facilitate the treatment of nervous system disorders, chronic pain and neuro-degenerative diseases.

Contact Information

Website
www.cytodel.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 430 East 29th Street
  • West Tower
  • New York, NY 10016
  • United States
+1 (646) 000-0000

CytoDel Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

CytoDel Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Accelerator/Incubator 00.00 Completed Generating Revenue
4. Later Stage VC (Series A) 16-Jan-2018 00.00 00.00 000.00 Completed Generating Revenue
3. Grant 01-Jul-2017 000.00 Completed Generating Revenue
2. Grant 01-Jan-2014 $224K Completed Generating Revenue
1. Accelerator/Incubator 13-Dec-2013 Completed Generating Revenue
To view CytoDel’s complete valuation and funding history, request access »

CytoDel Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-1 0,000,000 00.000000 00.00 00.00 00 00.00 00.00
Series A-2 000,000 00.000000 00.00 00.00 00 00.00 00
To view CytoDel’s complete cap table history, request access »

CytoDel Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Provider of a biotechnology platform intended to produce recombinant derivatives of botulinum neurotoxin. The company's
Drug Discovery
New York, NY
7 As of 2021
00.00
000000000000 00.00

00000

iscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim ven
0000000000000
Thousand Oaks, CA
00000 As of 0000
00.000
000000000000 00.000

000000

iqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commo
0000 000000000
Cambridge, MA
0000 As of 0000
000.00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CytoDel Competitors (4)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Amgen Formerly PE-Backed Thousand Oaks, CA 00000 00.000 000000000000 00.000
000000 Formerly VC-backed Cambridge, MA 0000 000.00 00000000000 000.00
000 00000 Corporation Indianapolis, IN 00000 000000 - 000
0000 000000 Corporation Frankfurt, Germany 0000
To view CytoDel’s complete competitors history, request access »

CytoDel Executive Team (3)

Name Title Board Seat Contact Info
Philip Band Ph.D Co-Founder, Chief Executive Officer & Board Member
Konstantin Ichtchenko Ph.D Co-Founder & Founding Scientist
You’re viewing 2 of 3 executive team members. Get the full list »

CytoDel Board Members (5)

Name Representing Role Since
André Gudger CytoDel Board Member 000 0000
Dennis Huang CytoDel Board Member 000 0000
Lawrence Remmel JD CytoDel Board Member 000 0000
Margery Fischbein Self Board Member 000 0000
Philip Band Ph.D CytoDel Co-Founder, Chief Executive Officer & Board Member 000 0000
To view CytoDel’s complete board members history, request access »

CytoDel Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CytoDel Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
NYU Innovation Venture Fund Accelerator/Incubator Minority 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
To view CytoDel’s complete investors history, request access »